4D Molecular Therapeutics... (FDMT)
| Bid | 3.1 |
| Market Cap | 151.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.98 |
| PE Ratio (ttm) | -1.1 |
| Forward PE | -1.29 |
| Analyst | Buy |
| Ask | 3.28 |
| Volume | 904,550 |
| Avg. Volume (20D) | 816,861 |
| Open | 2.95 |
| Previous Close | 2.99 |
| Day's Range | 2.98 - 3.40 |
| 52-Week Range | 2.87 - 29.27 |
| Beta | 2.82 |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...
Analyst Forecast
According to 9 analyst ratings, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $36, which is an increase of 1002.60% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $...
